Fosun Pharma (02196.HK): Approval granted for the registration of Levosalbutamol Hydrochloride Nebulization Solution.

According to the latest news from Zhitong Finance APP, Fosun Pharma (02196.HK) announced that its holding subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of levalbuterol hydrochloride nebulized inhalation solution (hereinafter referred to as "the drug"). The approved indication is for the treatment or prevention of bronchospasm due to reversible airway obstructive diseases in adults and children over the age of 6.